

# Accepted Manuscript

## Neutropenia with Fatal Outcome in a Multiple Sclerosis Patient 23 Days After Alemtuzumab Infusion

Konstantina G Yiannopoulou , Dimitra Papadimitriou ,  
Aikaterini Anastasiou , Marina Siakantaris

PII: S2211-0348(18)30133-0  
DOI: [10.1016/j.msard.2018.04.014](https://doi.org/10.1016/j.msard.2018.04.014)  
Reference: MSARD 831



To appear in: *Multiple Sclerosis and Related Disorders*

Received date: 18 March 2018  
Revised date: 17 April 2018  
Accepted date: 20 April 2018

Please cite this article as: Konstantina G Yiannopoulou , Dimitra Papadimitriou , Aikaterini Anastasiou , Marina Siakantaris , Neutropenia with Fatal Outcome in a Multiple Sclerosis Patient 23 Days After Alemtuzumab Infusion, *Multiple Sclerosis and Related Disorders* (2018), doi: [10.1016/j.msard.2018.04.014](https://doi.org/10.1016/j.msard.2018.04.014)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**HIGHLIGHTS**

- Alemtuzumab infusion – related early neutropenia in MS patients can be fatal
- Weekly blood test for the first two months after the first infusion should be provided
- Urgent hematologic consultation in case of febrile neutropenia is mandatory
- Absolute neutrophil count less than 500/MI should be treated with Granulocyte colony-stimulating factor

Download English Version:

<https://daneshyari.com/en/article/8647340>

Download Persian Version:

<https://daneshyari.com/article/8647340>

[Daneshyari.com](https://daneshyari.com)